Biovica International AB (publ) (FRA:9II)
Germany
· Delayed Price · Currency is EUR 0.0216
+0.0020 (10.20%)
At close: Dec 5, 2025
Biovica International AB Company Description
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally.
It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation.
It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Biovica International AB (publ)
| Country | Sweden |
| Founded | 2008 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 27 |
| CEO | Anders Rylander |
Contact Details
Address: Dag Hammarskjölds väg 54B Uppsala, Uppsala County 752 37 Sweden | |
| Phone | 46 1 84 44 48 30 |
| Website | biovica.com |
Stock Details
| Ticker Symbol | 9II |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | May - April |
| Reporting Currency | SEK |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Anders Rylander | Chief Executive Officer |
| Anders Moren | Chief Financial Officer |
| Hanna Ritzén | Chief Operating Officer |